Compare GBX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | ORIC |
|---|---|---|
| Founded | 1974 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | GBX | ORIC |
|---|---|---|
| Price | $46.33 | $11.05 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $50.67 | $18.78 |
| AVG Volume (30 Days) | 262.7K | ★ 1.2M |
| Earning Date | 01-07-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | ★ 27.96 | N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | ★ $3,240,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.77 | $3.90 |
| 52 Week High | $71.06 | $14.93 |
| Indicator | GBX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 40.42 |
| Support Level | $44.36 | $10.45 |
| Resistance Level | $47.35 | $12.14 |
| Average True Range (ATR) | 1.07 | 0.77 |
| MACD | 0.47 | -0.08 |
| Stochastic Oscillator | 79.77 | 26.05 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.